HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sanofi Starting US Cialis OTC Actual Use Study Soon While Tamiflu Switch Progress Delayed

French Pharma Reports €1.33Bn Q1 Consumer Health Sales Helped By Price Increases

Executive Summary

After 118.2% cough/cold sales growth leads 17% overall consumer business growth, Sanofi points to still stronger days ahead while keeping the business under the same roof with its pharmaceutical and vaccine divisions.

You may also be interested in...



Sanofi Awaiting Key Meeting With FDA To Recommence Cialis Switch

Sanofi is waiting to hear from FDA whether it has done enough to recommence its Cialis actual-use trial, which has been on hold for almost two years. The France-based firm gave an update on the Cialis switch program as it reported higher Consumer Healthcare sales in Q4.

Sanofi Consumer Healthcare Separation: Four Talking Points

Reviewing the news that Sanofi will exit the OTC market after setting up its Consumer Healthcare business to go it alone.

UK Cialis Rx-To-OTC Switch World-First For Sanofi, H2 2023 Launch Planned

The UK is the first country to allow OTC access to Sanofi's tadalafil-based erectile dysfunction drug Cialis following a successful switch. Approved as a pharmacy medicine, Sanofi will launch Cialis Together in the second half of the year. Cialis will compete against Viatris' sildenafil-based Viagra Connect in the men's sexual health and wellness category, which has seen a proliferation of products in recent months.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS152463

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel